PEER REVIEWED RESEARCH ARTICLES, 2009-2011

2011

Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, and Granoff DM. Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infection and Immunity, 2011: in press.

Giuntini S, Reason DC, and Granoff DM. The combined roles of human IgG subclass, alternative complement pathway activation, and epitope density on bactericidal activity of antibodies to meningococcal factor H binding protein. Infection and Immunity, 2011; Epub, 2011 Nov 7. PubMed ID: 22064712.
Abstract

Giuntini S, Reason DC, and Granoff DM. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infection and Immunity, 2011; 79:3751-59. PubMed ID: 21708990.
Abstract

Pajon R, Fergus AM, Koeberling O, Caugant DA, and Granoff DM. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. Public Library of Science Neglected Tropical Diseases, 2011; 5:e1302. PubMed ID: 21909444.
PDF

Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly D and Granoff DM. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine, 2011; 29:4728-34. PubMed ID: 21571025.
Abstract

Koeberling O, Delaney I and Granoff DM.  A critical threshold of meningococcal factor H binding protein is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clinical and Vaccine Immunology, 2011; Epub, 2011 March 2. PubMed ID: 21367981.
PDF

Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PR, Ram S and Granoff DM. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. Journal of Immunology, 2011; 186:3606-14. PubMed ID: 21325619.
Abstract

Vu DM, Wong TT, and Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine, 2011; 29:1968-1973. PubMed ID: 21241734.
Abstract

Dunphy KY, Beernink PT, Brogioni B, and Granoff DM. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infection and Immunity, 2011; 79:353-359. PubMed ID: 21041484.
PDF

2010

Beernink PT, Shaughnessy J, Ram S, and Granoff DM. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor H binding. Clinical and Vaccine Immunology, 2010; 17:1074-1078. PubMed ID: 20519444.
PDF

Granoff DM. Review of meningococcal group B vaccines. Clinical Infectious Diseases, 2010; 50(suppl 2):54-65 PubMed ID 20144017.
PDF

Pajon R, Beernink PT, Harrison LH, and Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine, 2010; 28:2122-2129 PubMed ID 20044056.
PDF

2009

Beernink PT and Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology, 2009; 155:2873-2883. PubMed ID 19574307.
PDF

Granoff DM. The relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine, 2009; 27(suppl 2):117-125. PubMed ID 19477054.
PDF

Plested J, Welsch JA, and Granoff DM. Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clinical and Vaccine Immunology, 2009; 16:785-791. PubMed ID 19339487.
PDF

Beernink PT, LoPasso C, Angiolillo A, Felici F, and Granoff DM. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Molecular Immunology, 2009; 46:1647-1653. PubMed ID 19286260.
PDF

Beernink PT, Caugant DA, Welsch JA, Koeberling O, and Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. Journal of Infectious Diseases, 2009; 199:1360-1368. PubMed ID 19302008.
PDF

Koeberling O, Giuntini S, Seubert A, and Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clinical and Vaccine Immunology 2009; 16:156-162. PubMed ID 19109451.
PDF

Granoff DM, Welsch JA, and Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infection and Immunity 2009; 77:764-769. PubMed ID 19047406.
PDF

CHAPTERS

Granoff DM and Gilsdorf JR. Neisseria meningitidis (Meningococcus). In: Kliegman RM, Stanton B, St. Geme J, Schor N, and Behrman RE, editors. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Saunders Elsevier; 2011. p 929-935.

Granoff DM, Harrison LH, and Borrow R. Meningococcal Vaccines. In: Plotkin SA, Orenstein WA, and Offit PA, editors. Vaccines. 5th ed. Philadelphia: Saunders Elsevier; 2008. p 399-434.

Revised: Monday, January 23, 2012 3:19 PM